Starczynowski Lab

Wang, T; Pine, AR; Kotini, AG; Yuan, H; Zamparo, L; Starczynowski, DT; Leslie, C; Papapetrou, EP. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell. 2021; 28:1074-1089.e7.

Serrano-Lopez, J; Hegde, S; Kumar, S; Serrano, J; Fang, J; Wellendorf, AM; Roche, PA; Rangel, Y; Carrington, LJ; Geiger, H; et al. Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics. eLife. 2021; 10.

Smith, MA; Culver-Cochran, AE; Adelman, ER; Rhyasen, GW; Ma, A; Figueroa, ME; Starczynowski, DT. TNFAIP3 Plays a Role in Aging of the Hematopoietic System. Frontiers in Immunology. 2020; 11.

Schieber, M; Marinaccio, C; Bolanos, LC; Haffey, WD; Greis, KD; Starczynowski, DT; Crispino, JD. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer Journal. 2020; 10.

Niederkorn, M; Agarwal, P; Starczynowski, DT. TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Experimental Hematology. 2020; 90:18-29.

Starczynowski, DT. HHEX expression drives AML development. Blood. 2020; 136:1575-1576.

Muto, T; Walker, CS; Choi, K; Hueneman, K; Smith, MA; Gul, Z; Garcia-Manero, G; Ma, A; Zheng, Y; Starczynowski, DT. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology. 2020; 21:535-545.

Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; et al. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Journal of Clinical Investigation. 2020; 130:2017-2023.

Niederkorn, M; Hueneman, K; Choi, K; Varney, ME; Romano, L; Pujato, MA; Greis, KD; Inoue, J; Meetei, R; Starczynowski, DT. TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. Cell Reports. 2020; 30:2776-2790.e6.

Sekeres, MA; Gore, SD; Stablein, DM; DiFronzo, N; Abel, GA; DeZern, AE; Troy, JD; Rollison, DE; Thomas, JW; Waclawiw, MA; et al. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia and Lymphoma. 2019; 60:3161-3171.

Melgar, KM; Jones, LM; Walker, M; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, K; Zhang, X; Sutter, P; et al. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood. 2019; 134:3934-3934.

Barreyro, L; Sampson, A; Hueneman, K; Choi, K; Christie, S; Wang, D; Huang, G; Starczynowski, DT. Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia. Blood. 2019; 134:2983-2983.

Goll, JB; Lindsley, RC; Hooper, WF; Bejar, R; Walker, J; Fulton, R; Abel, GA; Al Baghdadi, T; Deeg, HJ; DeZern, AE; et al. Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. Blood. 2019; 134:4271-4271.

Choudhary, GS; Smith, MA; Pellagatti, A; Bhagat, TD; Gordon, S; Pandey, S; Shah, N; Aluri, S; Booher, RN; Ramachandra, M; et al. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML. Blood. 2019; 134:4224-4224.

Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 2019; 11.

Rawat, R; Starczynowski, DT; Ntziachristos, P. Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease. Current Opinion in Cell Biology. 2019; 58:85-94.

Smith, MA; Choudhary, GS; Pellagatti, A; Choi, K; Bolanos, LC; Bhagat, TD; Gordon-Mitchell, S; Von Ahrens, D; Pradhan, K; Steeples, V; et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology. 2019; 21:640-650.

Barreyro, L; Chlon, TM; Starczynowski, DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018; 132:1553-1560.

Wei, Y; Zheng, H; Bao, N; Jiang, S; Bueso-Ramos, CE; Khoury, J; Class, C; Lu, Y; Lin, K; Yang, H; et al. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances. 2018; 2:2491-2504.

Culver-Cochran, AE; Starczynowski, DT. Chronic innate immune signaling results in ubiquitination of splicing machinery. Cell Cycle. 2018; 17:407-409.

Fang, J; Muto, T; Kleppe, M; Bolanos, LC; Hueneman, KM; Walker, CS; Sampson, L; Wellendorf, AM; Chetal, K; Choi, K; et al. TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis. Cell Reports. 2018; 22:1250-1262.

Smith, MA; Choudhary, G; Pellagatti, A; Choi, K; Bhagat, TD; Salomonis, N; Walter, MJ; Komurov, K; Sampson, ME S; Gordon, S; et al. Splicesome Mutant MDS and AML Cells Activate Innate Immune Signaling By Regulating the Expression of Therapeutically Targetable IRAK4 Isoforms. Blood. 2017; 130:785-785.

Kong, F; Liu, Z; Jain, VG; Shima, K; Suzuki, T; Muglia, LJ; Starczynowski, DT; Pasare, C; Bhattacharyya, S. Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages. Journal of Immunology. 2017; 199:3654-3667.

Niederkorn, M; Starczynowski, DT. GMP-ing to Spatial Conclusions about Emergency and Leukemic Myelopoiesis. Cell Stem Cell. 2017; 20:579-581.

Varney, ME; Choi, K; Bolanos, L; Christie, S; Fang, J; Grimes, LH; Maciejewski, JP; Inoue, J; Starczynowski, DT. Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome. Leukemia. 2017; 31:491-495.

Fang, J; Bolanos, LC; Choi, K; Liu, X; Christie, S; Akunuru, S; Kumar, R; Wang, D; Chen, X; Greis, KD; et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology. 2017; 18:236-245.